RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2912

Poliomyelitis

low confidenceDisorder

Publications

104,067

Trials

247

Interventional, condition-specific

Researchers

1,267

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare viral infection caused by any of three serotypes of wild human poliovirus (types 1, 2 and 3), which are part of the family of enteroviruses; and three serotypes of Sabin vaccine-derived polioviruses (types 1, 2 and 3) that have accumulated genetic changes and regained the ability to cause polio paralysis. wild type 2 and type 3 polioviruses have been certified eradicated, wild type 1 poliovirus continues to circulate in Pakistan and Afghanistan, and vaccine-derived polio viruses mainly circulate in sub-Saharan Africa.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

Polia · acute poliomyelitis · polio · poliomyelitis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    104,067 matched papers (38,538 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    247 matched on ClinicalTrials.gov (16 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

104,067

104,067 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

104,067 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

38,538 in the last 10 years · low confidence

Phrase hits: 104,067 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,267

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Zhang Y7 papers · 2026

    Expanded Program on Immunization, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China.

    Papers in Europe PMC
  2. 02
    Liu Y6 papers · 2026

    Expanded Program on Immunization, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China.

    Papers in Europe PMC
  3. 03
    Bandyopadhyay AS4 papers · 2026

    Bill and Melinda Gates Foundation, Polio Team, Seattle, Washington, USA.

    Papers in Europe PMC
  4. 04
    Blake IM4 papers · 2026

    School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.

    Papers in Europe PMC
  5. 05
    Grassly NC4 papers · 2026

    School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.

    Papers in Europe PMC
  6. 06
    Ivin YY4 papers · 2025

    Institute of Biomedical Chemistry, 10 Pogodinskaya str., 119121 Moscow, Russia.

    Papers in Europe PMC
  7. 07
    Kozlovskaya LI4 papers · 2025

    Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.

    Papers in Europe PMC
  8. 08
    Li X4 papers · 2026

    Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.

    Papers in Europe PMC
  9. 09
    Li Y4 papers · 2026

    Daiyue District Center for Disease Control and Prevention, Taian 271000, China.

    Papers in Europe PMC
  10. 10
    Maccari G4 papers · 2025

    Data Science for Health Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

247

interventional trials for this specific condition

247 interventional trials matched this specific condition name; 16 currently recruiting in our sample.

Data as of 27 July 2026

247 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.5th percentile).

low confidence · 99.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

247 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

22 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Poliomyelitis" OR "Polia" OR "acute poliomyelitis" OR "polio"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Poliomyelitis" OR "Polia" OR "acute poliomyelitis" OR "polio"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 247 interventional · 22 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (104067) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T21:39:42.628Z